In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results